» Articles » PMID: 12069960

Comparative Intracellular (THP-1 Macrophage) and Extracellular Activities of Beta-lactams, Azithromycin, Gentamicin, and Fluoroquinolones Against Listeria Monocytogenes at Clinically Relevant Concentrations

Overview
Specialty Pharmacology
Date 2002 Jun 19
PMID 12069960
Citations 45
Authors
Affiliations
Soon will be listed here.
Abstract

The activities of ampicillin, meropenem, azithromycin, gentamicin, ciprofloxacin, and moxifloxacin against intracellular hemolysin-positive Listeria monocytogenes were measured in human THP-1 macrophages and were compared with the extracellular activities observed in broth. All extracellular concentrations were adjusted to explore ranges that are clinically achievable in human serum upon conventional therapy. In broth, ampicillin, meropenem, and azithromycin were only bacteriostatic, whereas gentamicin, ciprofloxacin, and moxifloxacin were strongly bactericidal in a concentration-dependent manner. In cells, ampicillin, meropenem, azithromycin, and ciprofloxacin were slightly bactericidal (0.3- to 0.8-log CFU reductions), moxifloxacin was strongly bactericidal (2.1-log CFU reduction), and gentamicin was virtually inactive. The difference in the efficacies of moxifloxacin and ciprofloxacin in cells did not result from a difference in levels of accumulation in cells (6.96 +/- 1.05 versus 7.75 +/- 1.03) and was only partially explainable by the difference in the MICs (0.58 +/- 0.04 versus 1.40 +/- 0.17 mg/liter). Further analysis showed that intracellular moxifloxacin expressed only approximately 1/7 of the activity demonstrated against extracellular bacteria and ciprofloxacin expressed only 1/15 of the activity demonstrated against extracellular bacteria. Gentamicin did not increase the intracellular activities of the other antibiotics tested. The data suggest (i) that moxifloxacin could be of potential interest for eradication of the intracellular forms of L. monocytogenes, (ii) that the cellular accumulation of an antibiotic is not the only determinant of its intracellular activity (for fluoroquinolones, it is actually a self-defeating process as far as activity is concerned), and (iii) that pharmacodynamics (activity-to-concentration relationships) need to be considered for the establishment of efficacy against intracellular bacteria, just as they are for the establishment of efficacy against extracellular infections.

Citing Articles

Distinct transcriptome and traits of freshly dispersed cells.

Kalia M, Sauer K mSphere. 2024; 9(12):e0088424.

PMID: 39601567 PMC: 11656770. DOI: 10.1128/msphere.00884-24.


Camouflaging attenuated Salmonella by cryo-shocked macrophages for tumor-targeted therapy.

Wu L, Du Z, Li L, Qiao L, Zhang S, Yin X Signal Transduct Target Ther. 2024; 9(1):14.

PMID: 38195682 PMC: 10776584. DOI: 10.1038/s41392-023-01703-1.


Measurement of Accumulation of Antibiotics to Staphylococcus aureus in Phagosomes of Live Macrophages.

Kelly J, Dalesandro B, Liu Z, Chordia M, Ongwae G, Pires M Angew Chem Int Ed Engl. 2023; 63(3):e202313870.

PMID: 38051128 PMC: 10799677. DOI: 10.1002/anie.202313870.


Immune Response Modulation by Pseudomonas aeruginosa Persister Cells.

Hastings C, Himmler G, Patel A, Marques C mBio. 2023; 14(2):e0005623.

PMID: 36920189 PMC: 10128020. DOI: 10.1128/mbio.00056-23.


Immune response modulation by persister cells.

Hastings C, Himmler G, Patel A, Marques C bioRxiv. 2023; .

PMID: 36711557 PMC: 9881899. DOI: 10.1101/2023.01.07.523056.


References
1.
Sullivan J, Woodruff M, Lettieri J, Agarwal V, Krol G, Leese P . Pharmacokinetics of a once-daily oral dose of moxifloxacin (Bay 12-8039), a new enantiomerically pure 8-methoxy quinolone. Antimicrob Agents Chemother. 1999; 43(11):2793-7. PMC: 89563. DOI: 10.1128/AAC.43.11.2793. View

2.
Nichterlein T, Kretschmar M, Hof H . The ketolide antibiotic HMR 3647, a candidate substance for the treatment of systemic and intracerebral infections with Listeria monocytogenes. Zentralbl Bakteriol. 1999; 289(2):155-64. DOI: 10.1016/s0934-8840(99)80100-5. View

3.
Temple M, Nahata M . Treatment of listeriosis. Ann Pharmacother. 2000; 34(5):656-61. DOI: 10.1345/aph.19315. View

4.
Aminimanizani A, Beringer P, Jelliffe R . Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials. Clin Pharmacokinet. 2001; 40(3):169-87. DOI: 10.2165/00003088-200140030-00003. View

5.
Paillard D, Grellet J, Dubois V, Saux M, Quentin C . Discrepancy between uptake and intracellular activity of moxifloxacin in a Staphylococcus aureus-human THP-1 monocytic cell model. Antimicrob Agents Chemother. 2002; 46(2):288-93. PMC: 127041. DOI: 10.1128/AAC.46.2.288-293.2002. View